Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
PD-1/L1
Pharma
FDA rejects Hengrui, Elevar's PD-1 cancer drug combo—again
In handing down the second rejection, the FDA again raised manufacturing issues that required responses from Hengrui.
Angus Liu
Mar 21, 2025 3:25pm
Sun Pharma buys Checkpoint Therapeutics for up to $416M
Mar 10, 2025 10:23am
AstraZeneca says Imfinzi keeps stomach cancer from coming back
Mar 7, 2025 9:48am
Merck, Halozyme dig in for patent fight over injectable Keytruda
Mar 6, 2025 11:18am
Exelixis shifts focus as triplet misses OS mark in kidney cancer
Feb 18, 2025 1:30pm
BMS, Pfizer tout new standards in colorectal cancer subtypes
Jan 25, 2025 3:00pm
